Hangzhou-based neural interface startup Nanochap closed a RMB 500 million Series C+ funding round led by Gaorong Ventures. The deal marks the company's second major financing round this year, pushing its total capital raised to RMB 1 billion.
The fresh funds will accelerate human clinical trials for neural implants designed to restore lost eyesight.
Why It Matters
Commercial ImplicationsBrain-computer interfaces are transitioning from university labs into commercial clinical devices. While Elon Musk's Neuralink focuses heavily on general motor cortex chips, specialized startups are targeting specific sensory loss like blindness.
Nanochap's clinical progress demonstrates that high-density neural chips are clearing domestic medical hurdles at a rapid pace.
By The Numbers
Analysis & Engineering Implications for Technical Leaders
Key Developments & Takeaways
- Nanochap secured RMB 500 million in Series C+ funding, lifting its cumulative capital to RMB 1 billion.
- A 320-channel retinal implant has entered human clinical trials, with three patients already receiving surgical devices.
- Engineers are developing a 1,280-channel interface that connects directly to the visual cortex of the brain.
What this means for enterprise teams
The facts above come from TechNode. This section is Briefzio's interpretation of their implications for architecture, cost, and vendor decisions. It is one editor's judgment, clearly separated from the reported facts.
The Big Picture
Hangzhou-based biotech firm Nanochap has raised RMB 500 million in Series C+ financing. Gaorong Ventures led the round, with state-backed and private funds like PICC Equity, Monolith, and C&D Emerging Industry Investment joining in. This marks Nanochap's second major capital injection this year, pushing its lifetime funding to RMB 1 billion.
Founded in 2014, Nanochap builds specialized silicon microchips and neural implant systems. The company focuses squarely on restoring functional vision to patients through direct neural stimulation.
The Engineering Strategy
Restoring sight requires translating visual data into electrical impulses that human neurons can interpret. Nanochap is pursuing a dual-track hardware strategy to solve this challenge:
- Retinal stimulation: A 320-channel micro-interface designed to attach to damaged retinas. This device has officially entered human clinical testing, with surgeons already implanting it into three participants.
- Visual cortex targeting: A higher-density 1,280-channel interface that bypasses damaged optic nerves entirely to stimulate the visual center of the brain. This system remains in lab development, with human trials planned next.
By running both pathways simultaneously, Nanochap hedges biological and engineering risks. Retinal implants require less invasive surgery, while direct cortex implants can treat patients whose eyes and optic nerves are completely destroyed.
Why It Matters
The global brain-computer interface market is breaking into two distinct camps. One camp, led by firms like Neuralink and Synchron, targets digital interfaces and movement control. The other camp focuses on specific neuro-prosthetics to replace lost senses.
High-density silicon is the main bottleneck. Packing hundreds or thousands of channels onto biocompatible chips requires serious semiconductor packaging expertise. Nanochap's ability to raise back-to-back rounds in a tight venture market shows deep investor appetite for specialized medical hardware with proven clinical access.
Strategic Verdict
For engineering leaders and device makers, Nanochap shows the power of focus in deep tech. Building full-stack systems—from custom silicon to surgical tools—gives hardware companies an edge over pure-software neural decoders. Keep a close eye on clinical data from Chinese hospitals, where trial enrollment often moves faster than in Western regulatory systems.
Source: TechNode
Bottom line
Analysis by Hardeep Singh
•
Editor, Briefzio
Robotics unit economics: the real cost per hour
Capex is the easy number. Maintenance, teleoperation, utilization, and integration decide whether a robot costs less than the person it replaces.
Read the analysisInitial story events referenced from TechNode. Briefzio provides independent analysis of what the reported developments mean for enterprise architecture, cost, and vendor decisions.
Briefzio separates reported facts from analysis. Spotted an error? Request a correction — we respond within two business days.
Hardeep Singh is the founder and chief tech analyst at Briefzio. With a background in software engineering, distributed systems, and cloud architecture, he authors independent deep-dive technical commentary and strategic impact analyses across enterprise AI, hyperscalers, and autonomous technologies across North America.
